General presentation of BioNano Genomics
To be able to anticipate future changes in BioNano Genomics' share price, you also need to have a good understanding of the company and its business. This will help you understand how the company is likely to change over time depending on market conditions.
BioNano Genomics Inc. is an American company that provides optical genome mapping solutions for genome analysis.
Specifically, the company offers tools and services based primarily on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. The group also offers diagnostic testing services for pediatric patients with suspected neurodevelopmental disorders.
The Saphyr system, owned by BioNano Genomics, is an ultra-sensitive and ultra-specific structural variation detection platform that enables researchers and clinicians to search for diagnostics and therapeutic targets and to streamline the identification of structural changes in chromosomes. The system consists of an instrument, consumables for the chip, reagents and a suite of data analysis tools.
The company also markets proprietary molecular genetic diagnostic services for patients with clinical presentations consistent with neurodevelopmental disorders, including autism spectrum disorders and other child developmental disorders.
The BioNano Genomics group currently employs 147 people.
68% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro